Why Are Apellis Pharmaceuticals Shares More Than 20% Down Today?

Comments
Loading...

Apellis Pharmaceuticals Inc APLS shares are trading lower amid safety concerns regarding the company's newly launched Syfovre (pegcetacoplan injection) for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Raymond James analyst notes that the ASRS Research and Safety in Therapeutics (ReST) Committee distributed a notification to its members on Saturday indicating:

  • Six cases of occlusive retinal vasculitis have been observed since Syfovre's launch in March this year.
  • All events observed after the first injection, 7-13 days post-injection.
  •  No specific product lots were implicated. 

Moreover, the communication indicates that ~60,000 vials of Syfovre have been distributed since FDA approval. 

The analyst spoke with Apellis, who confirmed the details. 

The 60k vials distributed since launch exceeds the already Street-high 2Q23 estimate by ~15k vials, implying 2Q23 Syfovre revenue could be over $80 million (vs. Raymond James's estimate of $54 million and Street consensus $34 million).

In Q1 FY23, Apellis reported $18.4 million in Syfovre U.S. net product revenue.

Price Action: APLS shares are down 22.80% at $65.25 on the last check Monday.

Market News and Data brought to you by Benzinga APIs
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm

Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!